Instrument Inactif

Autres langues Vifor Pharma AG Other OTC

Actions

GNHAY

US92674R1023

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	19/04
CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	02/05/23
Court Cancels Public Shares of Vifor Pharma after Merger with CSL	14/12/22
Vifor-Aktien werden am 23. Dezember dekotiert	14/12/22
Cancellation of remaining publicly held registered shares of Vifor Pharma AG	14/12/22
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	28/11/22
Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	25/11/22
Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	03/11/22
Approval of extension of exemptions from SIX disclosure and publicity obligations	20/10/22
Australia's CSL raises annual profit forecast on Swiss acquisition	17/10/22
Global markets live: Darktrace, Intel, Twitter, Meta, Uber...	12/10/22
Bolsa de Madrid: El peso de las palabras	12/10/22
Vifor erhält Genehmigung für Dekotierung von der Schweizer Börse	12/10/22
Vifor Pharma Gets Approval To Delist From Swiss Bourse	12/10/22
Approval of delisting of Vifor Pharma AG's registered shares	12/10/22
Kapruvia® (Difelikefalin) jetzt in Deutschland für Hämodialysepatient:innen mit CKD-assoziiertem Pruritus erhältlich	06/10/22
Isabelle Welton nuova presidente del cda della NZZ	04/10/22
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	28/09/22
Tavneos® erhält Swissmedic-Zulassung für die Behandlung ANCA-assoziierter Vaskulitis	27/09/22
Schweizer Unternehmen dürften auch aktuelle Krise gut überstehen	08/09/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Vifor Pharma AG Other OTC

Actions

GNHAY

US92674R1023

Autres langues

Filtres